• UCF Research & Commercialization
  • Sponsored Programs
  • Tech Transfer
  • Technology Incubator
  • Compliance
  • Research Foundation
  • Centers
  •     |     Search
     
    Print  
    Available Technologies / Life Sciences / LifeScienceTech - #7577, 7313, 7610, 7656
     
    Oxazole-based Small Molecule Stat3 Inhibitors and Suppressors of the Tumor Process 
     PDF Version  

     

    Background
    The signal transducers and activators of transcription (STATs) are a class of transcription factor proteins that regulate cell growth and survival. A total of seven STAT isoforms, encoded in distinct genes, have been identified in mammalian cells. Stat3 protein isoform is known to directly up-regulate Bcl-xL, Mcl-1, cyclin D1/D2 and c-myc, contributing to compromised regulation by stimulating cell proliferation and preventing apoptosis in numerous human cancers.  Stat3 activation occurs via phosphorylation of tyrosine 705, which promotes STAT dimer formation through STAT phosphotyrosine-SH2 domain interactions. These STAT dimers translocate to the nucleus, where they regulate gene expression. Constitutive Stat3 activity mediates dysregulated growth and survival, angiogenesis, as well as suppresses the host's immune surveillance of tumors and represents a valid target for small molecule anti-cancer design.  

    Invention

    A novel oxazole-based peptidomimetic, designated S3I-M2001, was synthesized and shown to be a selective disruptor of Stat3:Stat3 dimerization and inhibitor of Stat3 activation in STAT3-dependent human cancer cell lines.  In addition, other analogs have been designed, synthesized, tested, and shown to be effective inhibitors of Stat3 dimerization.

    Application
    S3I-M2001 is a potential therapeutic intervention for malignant human cancer. S3I-M2001, an inhibitor of Stat3 activation, can be used to develop drugs capable of targeting cells with constitutively active Stat3, leading to tumor regression.

    Advantages

    •    STAT3 inhibitors can be used to sensitize human cancers with constitutively active STAT3 to existing chemotherapeutic agents, potentially reducing the side effects associated with conventional, aggressive chemotherapy.
    •    S3I-M2001 could be made into a pharmaceutically acceptable composition and be administered to patients.

    Lead Inventor
    James Turkson, Ph.D.

    Selected References

    Fletcher S, Turkson J, Gunning PT.  Molecular approaches towards the inhibition of the signal transducer and activator of transcription 3 (Stat3) protein. ChemMedChem. 2008; 3(8): 1159-68.

    Siddiquee KA, Gunning PT, et al.  An oxazole-based small-molecule Stat3 inhibitor modulates Stat3 stability and processing and induces antitumor cell effects. ACS Chem Biol. 2007; 2(12): 787-98.

    Al Zaid Siddiquee K, Turkson J. STAT3 as a target for inducing apoptosis in solid and hematological tumors.Cell Res. 2008; 18(2): 254-67. Review.

    Contact

    Attn: Svetlana Shtrom, Ph.D., MBA
    University of Central Florida
    Office of Research and Commercialization
    12201 Research Parkway, Suite 501
    Orlando, Fl 32826-3246
    Phone: 407.823.5150
    Fax: 407.823.3299
    sshtrom@mail.ucf.edu


    UCF ID # 7577/7313, 7610, 7656

     
     
    Print  
     
    Print  
  • Home
  • Contact Us
  • Site Credit
  • © 2008 UCF Office of Research & Commercialization All Rights Reserved
    UCF Office of Research & Commercialization | 12201 Research Parkway, Suite 501 | Orlando, FL 32826
    Phone: 407.823.3778 | Fax: 407.823.3299